NCT05560841

Effectiveness and Safety of Nailner Brush 2in1 in Onychomycosis

Name: Clinical Trial NCT05560841
Creator: Karo Pharma AB
Keywords: Onychomycosis, topical treatment, device, clinical trial, Tunisia

Prospective, Evaluator Blinded Clinical Investigation to Evaluate the Effectiveness and Safety of Nailner Brush 2-in-1 in the Treatment of Onychomycosis

Karo Pharma AB·ClinicalTrials.gov·device·Device trialRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Onychomycosis
Drug/Device/Intervention: topical treatment
Study type: Interventional
Intervention type: device

Sponsor & location

Primary sponsor: Karo Pharma AB
Location: Ben Arous,Tunis, Tunisia

Timeline & enrollment

Phase: N/A
Start date: Aug 01, 2022
End date: May 30, 2023
Enrollment: 50 participants

Primary outcome

To evaluate the effectiveness of Nailner Brush 2-in-1 in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface after 6 months of treatment compared to baseline

Summary

Evaluate the effectiveness of Nailner Brush 2-in-1 in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface after 6 months of treatment compared to baseline.

ICD-10 classifications

OnychogryphosisChromomycosis, unspecifiedOnycholysisActinomycosisBlastomycosis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05560841
Type: Device Trial

About this record

Access comprehensive clinical trial information for NCT05560841 through Pure Global AI's free database. This phase not specified trial is sponsored by Karo Pharma AB and is currently Recruiting. The study focuses on Onychomycosis. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.